Abstract:Liver X receptors (LXRs) have been recognized as a promising therapeutic target for atherosclerosis; however, their role in insulin sensitivity is controversial. Adiponectin plays a unique role in maintaining insulin sensitivity. Currently, no systematic experiments elucidating the role of LXR activation in insulin function based on adiponectin signaling have been reported. Here, we investigated the role of LXR activation in insulin resistance based on adiponectin signaling, and possible mechanisms. C57BL/6 mice maintained on a regular chow received the LXR agonist, T0901317 (30 mg/kg.d) for 3 weeks by intraperitoneal injection, and differentiated 3T3-L1 adipocytes were treated with T0901317 or GW3965. T0901317 treatment induced significant insulin resistance in C57BL/6 mice. It decreased adiponectin gene transcription in epididymal fat, as well as serum adiponectin levels. Activity of AMPK, a key mediator of adiponectin signaling, was also decreased, resulting in decreased Glut-4 membrane translocation in epididymal fat. In contrast, adiponectin activity was not changed in the liver of T0901317 treated mice. In vitro, both T0901317 and GW3965 decreased adiponectin expression in adipocytes in a dose-dependent manner, an effect which was diminished by LXR alpha silencing. ChIP-qPCR studies demonstrated that T0901317 decreased the binding of PPAR gamma to the PPAR-responsive element (PPRE) of the adiponectin promoter in a dose-dependent manner. Furthermore, T0901317 exerted an antagonistic effect on the expression of adiponectin in adipocytes co-treated with 3 mu M Pioglitazone. In luciferase reporter gene assays, T0901317 dose-dependently inhibited PPRE-Luc activity in HEK293 cells co-transfected with LXR alpha and PPAR gamma. These results suggest that LXR activation induces insulin resistance with decreased adiponectin signaling in epididymal fat, probably due to negative regulation of PPAR gamma signaling. These findings indicate that the potential of LXR activation as a therapeutic target for atherosclerosis may be limited by the possibility of exacerbating insulin resistance-related disease.

Recent Advances on Liver X Receptors

Liver X receptors as potential therapeutic targets for multiple diseases.

Liver X receptors bridge hepatic lipid metabolism and inflammation.

Liver X Receptors Regulate Cholesterol Metabolism and Immunity in Hepatic Nonparenchymal Cells

Liver X receptor: a potential target in the treatment of atherosclerosis

Liver X Receptors: Regulators of Cholesterol Metabolism, Inflammation, Autoimmunity, and Cancer

Molecular mechanism of liver X receptors in cancer therapeutics

Liver X receptors link lipid metabolism and inflammation

Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

The Emerging Role of Constitutive Androstane Receptor and Its Cross Talk with Liver X Receptors and Peroxisome Proliferator-Activated Receptor A in Lipid Metabolism.

Liver X receptors conserve the therapeutic target potential for the treatment of rheumatoid arthritis

Liver X Receptors (LXRs) in cancer-an Eagle's view on molecular insights and therapeutic opportunities

LXR agonists: new potential therapeutic drug for neurodegenerative diseases

Untangling the inflammatory responses of liver x receptor (LXR) activation in human macrophages

Liver X Receptors (lxrs) Regulate Apolipoprotein Aiv-Implications of the Antiatherosclerotic Effect of Lxr Agonists

Aberrant activation of liver X receptors impairs pancreatic beta cell function through upregulation of sterol regulatory element-binding protein 1c in mouse islets and rodent cell lines

Activation of Liver X Receptors Inhibits Pancreatic Islet Beta Cell Proliferation Through Cell Cycle Arrest

Regulatory mechanism underlying liver X receptor effects on the tumor microenvironment, inflammation and tumorigenesis

Advance in the research on several nuclear receptors related to bile acid metabolism

Abstract 1453: LXR-623, a Novel Liver X Receptor Modulator, Displays Neutral Lipid Effects in Cholesteryl Ester Transfer Protein-expressing Species and Inhibits Atherosclerotic Lesion Progression in Low Density Lipoprotein Receptor Knockout Mice